Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
21.29 +0.32 (+1.53%) 01/23/25 [NASDAQ]
21.27 x 500 21.86 x 100
Realtime by (Cboe BZX)
21.27 x 500 21.86 x 100
Realtime 21.29 unch (unch) 17:16 ET
Quote Overview for Thu, Jan 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
21.03
Day High
21.32
Open 21.26
Previous Close 20.97 20.97
Volume 860,500 860,500
Avg Vol 1,021,515 1,021,515
Stochastic %K 61.36% 61.36%
Weighted Alpha -26.63 -26.63
5-Day Change +1.06 (+5.24%) +1.06 (+5.24%)
52-Week Range 19.85 - 31.88 19.85 - 31.88
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,877,275
  • Shares Outstanding, K 661,768
  • Annual Sales, $ 2,392 M
  • Annual Income, $ 631,910 K
  • EBIT $ 903 M
  • EBITDA $ 946 M
  • 60-Month Beta 0.97
  • Price/Sales 4.93
  • Price/Cash Flow 17.58
  • Price/Book 3.07

Options Overview Details

View History
  • Implied Volatility 49.96% ( -22.99%)
  • Historical Volatility 37.82%
  • IV Percentile 48%
  • IV Rank 36.40%
  • IV High 112.31% on 06/26/24
  • IV Low 14.29% on 05/10/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 4,286
  • Open Int (30-Day) 4,232

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.38
  • Number of Estimates 6
  • High Estimate 0.52
  • Low Estimate 0.28
  • Prior Year 0.36
  • Growth Rate Est. (year over year) +5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.89 +7.04%
on 01/15/25
Period Open: 20.76
22.27 -4.42%
on 01/07/25
+0.53 (+2.55%)
since 12/23/24
3-Month
19.85 +7.25%
on 12/16/24
Period Open: 22.73
23.47 -9.29%
on 11/11/24
-1.44 (-6.34%)
since 10/23/24
52-Week
19.85 +7.25%
on 12/16/24
Period Open: 27.96
31.88 -33.22%
on 03/13/24
-6.67 (-23.86%)
since 01/23/24

Most Recent Stories

More News
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily...

NVO : 81.10 (+0.66%)
GMAB : 21.29 (+1.53%)
LLY : 766.60 (+1.67%)
ABBV : 170.67 (+0.87%)
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?

Investors in Genmab A/S GMAB need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $17.50 Call had some of the highest implied volatility...

GMAB : 21.29 (+1.53%)
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie’s...

NVO : 81.10 (+0.66%)
GMAB : 21.29 (+1.53%)
LLY : 766.60 (+1.67%)
ABBV : 170.67 (+0.87%)
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart below.ABBV...

NVO : 81.10 (+0.66%)
LLY : 766.60 (+1.67%)
ABBV : 170.67 (+0.87%)
GMAB : 21.29 (+1.53%)
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 26.44 (+1.65%)
ABBV : 170.67 (+0.87%)
JNJ : 146.64 (+0.94%)
RHHBY : 38.0700 (+0.58%)
GMAB : 21.29 (+1.53%)
AZN : 68.60 (+0.59%)
DSNKY : 28.4400 (-1.22%)
MRK : 96.63 (+0.99%)
LLY : 766.60 (+1.67%)
NVO : 81.10 (+0.66%)
Why Shares of Iovance Biotherapeutics Dropped Thursday

The biotech stock's lead therapy is looking at some competition.

SGEN : 228.74 (-0.07%)
GMAB : 21.29 (+1.53%)
IOVA : 6.19 (+3.34%)
Why Shares of Zai Lab Limited Were Jumping on Tuesday

Zai Lab's shares benefited from positive clinical trial news.

ZLAB : 25.64 (-3.72%)
SGEN : 228.74 (-0.07%)
GMAB : 21.29 (+1.53%)
Is AbbVie Still a Good Dividend Stock to Buy?

Find out if AbbVie can overcome sinking sales of its top-selling product.

ABT : 123.22 (+4.62%)
RHHBY : 38.0700 (+0.58%)
AMGN : 277.88 (+1.62%)
GMAB : 21.29 (+1.53%)
ABBV : 170.67 (+0.87%)
3 Things About Johnson & Johnson Every Smart Investor Knows

The company has been a strong value stock but faces big changes this year.

KVUE : 20.75 (unch)
AMGN : 277.88 (+1.62%)
GMAB : 21.29 (+1.53%)
JNJ : 146.64 (+0.94%)
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?

In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.

ABBV : 170.67 (+0.87%)
GMAB : 21.29 (+1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 21.69
2nd Resistance Point 21.50
1st Resistance Point 21.40
Last Price 21.29
1st Support Level 21.11
2nd Support Level 20.92
3rd Support Level 20.82

See More

52-Week High 31.88
Fibonacci 61.8% 27.28
Fibonacci 50% 25.86
Fibonacci 38.2% 24.45
Last Price 21.29
52-Week Low 19.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar